当前位置:首页 >财报库 > 报告详情

美德纳Moderna(MRNA)2025年第一季度财报「NASDAQ」(英文版)(41页).pdf

上传人: Kell****reet 编号:653906 2025-05-20 41页 797.90KB

下载:

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,DC 20549FORM10-Q(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF

2、1934For the transition period from _ to _Commission File Number:001-38753Moderna,Inc.(Exact Name of Registrant as Specified in Its Charter)Delaware81-3467528(State or Other Jurisdiction of Incorporation orOrganization)(IRS EmployerIdentification No.)325 Binney StreetCambridge,Massachusetts02142(Addr

3、ess of Principal Executive Offices)(Zip Code)(617)714-6500(Registrants Telephone Number,Including Area Code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading symbol(s)Name of each exchange on which registeredCommon stock,par value$0.0001 per shareMRNAThe Nasdaq Sto

4、ck Market LLCIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject

5、 to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of thischapter)during the preceding 12 months(or for such shorter pe

6、riod that the registrant was required to submit such files).Yes No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smaller reporting company,or an emerging growth company.Seethe definitions of“large accelerated filer”,“acceler

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
Moderna, Inc.是一家生物技术公司,专注于开发基于信使RNA(mRNA)的新药。2025年3月31日,Moderna的资产总额为127亿美元,其中包括现金及现金等价物16.23亿美元,投资43.52亿美元,应收账款7800万美元,存货1.28亿美元,预付费用及其他流动资产5.85亿美元。负债总额为26.38亿美元,其中包括应付账款2.26亿美元,应计负债10.01亿美元,递延收入1.54亿美元。Moderna的股东权益总额为100.66亿美元。2025年第一季度,Moderna的净亏损为9.71亿美元,每股亏损2.52美元。Moderna的主要收入来源为COVID疫苗(Spikevax)和RSV疫苗(mRNA-1345)的销售。
现代公司2025年第一季度财务状况如何? 现代公司新冠疫苗和RSV疫苗销售情况如何? 现代公司未来流感疫苗研发进展如何?
客服
商务合作
小程序
服务号
折叠